AstraZeneca and PTC Therapeutics have entered into a research collaboration for the discovery and development of novel therapies using PTC’s GEMS™ (Gene Expression Modulation by Small molecules) technology platform. The deal will initially focus on cancer and could be extended to up to eight targets across different therapeutic areas. AstraZeneca retains global commercialisation rights but PTC could participate in the development of select product candidates emerging from the collaboration.